Short Interest in Autolus Therapeutics plc (NASDAQ:AUTL) Increases By 8.7%

Autolus Therapeutics plc (NASDAQ:AUTL) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 9,110,000 shares, a growth of 8.7% from the January 15th total of 8,380,000 shares. Based on an average daily trading volume, of 1,710,000 shares, the days-to-cover ratio is presently 5.3 days.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Jane Street Group LLC bought a new position in shares of Autolus Therapeutics in the fourth quarter worth about $26,000. Barclays PLC grew its position in shares of Autolus Therapeutics by 1,094.3% during the fourth quarter. Barclays PLC now owns 11,859 shares of the company’s stock worth $28,000 after purchasing an additional 10,866 shares in the last quarter. Dumont & Blake Investment Advisors LLC purchased a new position in Autolus Therapeutics during the 4th quarter valued at approximately $35,000. Arkadios Wealth Advisors purchased a new position in Autolus Therapeutics during the 4th quarter valued at approximately $47,000. Finally, Capstone Investment Advisors LLC purchased a new position in Autolus Therapeutics during the 3rd quarter valued at approximately $51,000. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Trading Up 5.2 %

NASDAQ AUTL opened at $2.04 on Tuesday. Autolus Therapeutics has a 12 month low of $1.87 and a 12 month high of $7.31. The stock has a market cap of $542.82 million, a P/E ratio of -1.69 and a beta of 2.02. The stock’s fifty day moving average price is $2.29 and its 200-day moving average price is $3.24.

Analysts Set New Price Targets

A number of research analysts have weighed in on AUTL shares. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, January 13th. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Finally, Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $10.40.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.